SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* TRYNISKI MARK E (Last) (First) (Middle) 1964 PENFOLD WAY (Street) BALDWINSVILLE NY 13027 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CONMED CORP [ CNMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/16/2021
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/16/2021		M		1,000	A	$27.63	43,889	D
Common Stock	02/16/2021		F		229	D	$120.69	43,660	D
Common Stock	02/16/2021		M		1,000	A	$26.09	44,660	D
Common Stock	02/16/2021		F		217	D	$120.69	44,443	D
Common Stock	02/16/2021		M		1,000	A	$32.93	45,443	D
Common Stock	02/16/2021		F		273	D	$120.69	45,170	D
Common Stock	02/16/2021		M		1,000	A	$39.64	46,170	D
Common Stock	02/16/2021		F		329	D	$120.69	45,841	D
Common Stock	02/16/2021		M		1,000	A	$53.83	46,841	D
Common Stock	02/16/2021		F		462	D	$120.69	46,379	D
Common Stock	02/16/2021		M		7,195	A	$41.06	53,574	D
Common Stock	02/16/2021		F		2,420	D	$122.1	51,154	D
Common Stock	02/16/2021		S		2,230	D	$120.88(1)	48,924	D
Common Stock	02/16/2021		S		2,545	D	$121.31(2)	46,379	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Sars (Stock Appreciation Rights)	$27.63	02/16/2021		M			1,000	06/01/2012(3)	06/01/2021	Common Stock	1,000	$0	0	D
Sars (Stock Appreciation Rights)	$26.09	02/16/2021		M			1,000	06/01/2013(3)	06/01/2022	Common Stock	1,000	$0	0	D
Sars (Stock Appreciation Rights)	$32.93	02/16/2021		M			1,000	06/01/2014(3)	06/01/2023	Common Stock	1,000	$0	0	D
Sars (Stock Appreciation Rights)	$39.64	02/16/2021		M			1,000	06/01/2015(4)	09/11/2024	Common Stock	1,000	$0	0	D
Sars (Stock Appreciation Rights)	$55.7	02/16/2021		M			1,000	06/01/2016	06/01/2025	Common Stock	1,000	$0	0	D
Options To Purchase Common Stock	$41.06	02/16/2021		M			7,195	06/01/2017(5)	06/01/2026	Common Stock	7,195	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.56 to $121.15. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.21 to $122.11. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

3. The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.

4. The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting upon completion of the term of service.

5. The incentive stock options ("ISOs") were granted under the Company's 2016 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.

	Daniel S. Jonas for Mark E. Tryniski by Power of Attorney	02/17/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.